bioRxiv preprint doi: https://doi.org/10.1101/385104; this version posted August 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Myoviridae Phage PDX Kills Enteroaggregative Escherichia coli without Human Microbiome Dysbiosis Leah C. S. Cepko a, Eliotte E. Garling b, Madeline J. Dinsdale c, William P. Scott c, Loralee Bandy c, Tim Nice d, Joshua Faber-Hammond c, and Jay L. Mellies c, a 320 Longwood Avenue, Enders Building, Department of Infectious Disease, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115. U.S.A. b Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109. U.S.A. c Biology Department, Reed College, 3203 SE Woodstock Blvd., Portland, OR, 97202. U. S. A. d Department of Molecular Microbiology & Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239. For correspondence: Jay Mellies, Ph.D. Biology Department Reed College 3202 SE Woodstock Blvd. Portland, OR 97202 USA Telephone: 503.517.7964 Fax: 503.777.7773 Email:
[email protected] Running title: Phage therapy against EAEC without dysbiosis Keywords: bacteriophage (phage), phage therapy, EAEC, Caudovirales, MDR, Myoviridae, Escherichia virus, microbiome, dysbiosis antibiotic alternatives. bioRxiv preprint doi: https://doi.org/10.1101/385104; this version posted August 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Purpose. To identify therapeutic a bacteriophage that kills diarrheagenic enteroaggregative Escherichia coli (EAEC) while leaving the human microbiome intact.